Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abaloparatide subcutaneous in men with osteoporosis (Phase 3, randomized, double-blind, placebo-controlled)
2017-004220-30Phase 3Completed
- Sponsor
- Radius Health Inc
- Start
- Jun 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing Abaloparatide-SC 80 µg daily with Placebo SC (2 arms). Primary endpoint: Percent change from baseline in lumbar spine BMD at 12 months. Started Jun 2018; status: completed.
02
Drugs
abaloparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2017-004220-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004220-30.